Regenxbio Inc (RGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -200,605 | -138,737 | -66,676 | -280,321 | -220,386 |
| Depreciation Amortization | 13,914 | 9,675 | 4,860 | 17,621 | 12,592 |
| Accounts receivable | 566 | 7,108 | 9,495 | 4,822 | -22 |
| Accounts payable and accrued liabilities | -4,011 | -14,108 | -3,103 | 18,790 | 16,883 |
| Other Working Capital | -20,110 | -19,487 | -29,612 | 13,977 | 7,176 |
| Other Operating Activity | 32,599 | 27,309 | 4,118 | 17,623 | 15,641 |
| Operating Cash Flow | $-177,647 | $-128,240 | $-80,918 | $-207,488 | $-168,116 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 165,803 | 125,707 | 67,912 | 18,795 | -13,375 |
| PPE Investments | -8,834 | -7,395 | -4,818 | -30,724 | -25,254 |
| Investing Cash Flow | $156,969 | $118,312 | $63,094 | $-11,929 | $-38,629 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 8,012 | 1,803 | 1,054 | 4,546 | 4,503 |
| Other Financing Activity | -31,016 | -20,002 | -10,091 | -33,386 | -24,423 |
| Financing Cash Flow | $-23,004 | $-18,199 | $-9,037 | $-28,840 | $-19,920 |
| Beginning Cash Position | 98,982 | 98,982 | 98,982 | 347,239 | 347,239 |
| End Cash Position | 55,300 | 70,855 | 72,121 | 98,982 | 120,574 |
| Net Cash Flow | $-43,682 | $-28,127 | $-26,861 | $-248,257 | $-226,665 |
| Free Cash Flow | |||||
| Operating Cash Flow | -177,647 | -128,240 | -80,918 | -207,488 | -168,116 |
| Capital Expenditure | -8,834 | -7,395 | -4,818 | -30,724 | -25,254 |
| Free Cash Flow | -186,481 | -135,635 | -85,736 | -238,212 | -193,370 |